• shareIcon

Zydus Cadilla launches affordable biosimilar of Adalimumab in India

Latest By Meenakshi Chaudhary , Onlymyhealth editorial team / Dec 10, 2014
Zydus Cadilla launches affordable biosimilar of Adalimumab in India

Zydus Cadilla has lauched biosimilar of the world’s most selling drug in India. The biosimilar is expected to cost around fifth of the cost of the original drug, which will make it more affordable for Indian patients.

Zydus Cadila Healthcare Ltd. has on Tuesday launched a biosimilar version of it’s popular drug Adalimumab, the fully human anti-TNF alpha monoclonal antibody. The drug is branded and sold as Humira in the US for treating rheumatoid arthritis and other auto immune disorders. Zydus Cadila has decided to sell the drug under the brand name, Exemptia as a economical option for people in India who are seeking treatments for auto immune disorders such as rheumatoid arthritis.  

Health newsA biosimilar of a drug is a cheap copy of the biotech drugs made from proteins and other large molecules, but have similar level of efficacy and safety of the originator drug. Biosimilars of drugs are several times more affordable and accessible to original drugs. The biosimilar, developed by the scientists at the Zydus Research Centre, has been approved by the Drug Controller General of India for treatment of auto immune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and Ankylosing Spondylitis.

Adalimumab, approved globally in 2002, has been the largest selling drug since it’s launch.  While a vial of the original version Humira, costs around 55,000 indian rupees, the biosimilar will cost around 10,000 or more. The launch of the biosimilar is a good news as there are more than 12 million patients in India suffering from auto immune disorders. However, that is another matter that around 70% of Indian population lives on less than 100 rupees a day and would still not be able to afford the biosimilar.

During the launch Dr Sharvil Patel, deputy managing director of Zydus Cadila, said, “At Zydus, we believe that innovations must bridge unmet healthcare needs and provide solutions to patients who are suffering from disease and disability especially in such chronic conditions. This therapy will offer a new lease of life to millions in India who did not have access to this therapy so far. We are happy to offer them hope, freedom from pain and better quality of life through Exemptia.”  "We are working towards being among the first wave of the launch of this drug's biosimilars globally," Patel added. The company is hoping to launch the medicine in the US in 2019. Several other companies in India are working on developing biosimilars for otherwise costly original drugs.

 

Image Courtesy : Getty

Read more on Health News

 
Disclaimer:

All possible measures have been taken to ensure accuracy, reliability, timeliness and authenticity of the information; however Onlymyhealth.com does not take any liability for the same. Using any information provided by the website is solely at the viewers’ discretion. In case of any medical exigencies/ persistent health issues, we advise you to seek a qualified medical practitioner before putting to use any advice/tips given by our team or any third party in form of answers/comments on the above mentioned website.